TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

Investors in TauRx Pharma have exercised warrants worth around $119 million, adding to the biotech's financial resources as it prepares regulatory filings for tau-targeting Alzheimer's drug ...

Mar. 12, 2025 — In developing hearts, cells shuffle around, bumping into each other to find their place, and the stakes are high: pairing with the wrong cell could mean the difference between a ...